Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Concurrent Amphetamine and Methamphetamine Use Among Clients of Opioid Maintenance Treatment Programs in Golestan, Iran

Ahmad Danesh 1 and Alireza Noroozi ORCID 2 , 3 , *
Authors Information
1 Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Golestan, Iran
2 Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
3 Neuroscience and Addiction Studies Department, School of Advance Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: 13 (2); e74234
  • Published Online: June 12, 2019
  • Article Type: Original Article
  • Received: May 3, 2018
  • Revised: February 15, 2019
  • Accepted: May 21, 2019
  • DOI: 10.5812/ijpbs.74234

To Cite: Danesh A, Noroozi A. Concurrent Amphetamine and Methamphetamine Use Among Clients of Opioid Maintenance Treatment Programs in Golestan, Iran, Iran J Psychiatry Behav Sci. Online ahead of Print ; 13(2):e74234. doi: 10.5812/ijpbs.74234.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Massaro LTS, Abdalla RR, Laranjeira R, Caetano R, Pinsky I, Madruga CS. Amphetamine-type stimulant use and conditional paths of consumption: Data from the Second Brazilian National Alcohol and Drugs Survey. Braz J Psychiatry. 2017;39(3):201-7. doi: 10.1590/1516-4446-2015-1894. [PubMed: 28700012].
  • 2. Safer DJ. Recent trends in stimulant usage. J Atten Disord. 2016;20(6):471-7. doi: 10.1177/1087054715605915. [PubMed: 26486603].
  • 3. Rognli EB, Bramness JG, Skurtveit S, Bukten A. Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample. J Subst Abuse Treat. 2017;74:42-7. doi: 10.1016/j.jsat.2016.12.007. [PubMed: 28132699].
  • 4. Zhuang SM, Chen F. Chinese adolescents and youth with methamphetamine dependence: Prevalence and concurrent psychological problems. Nurs Res. 2016;65(2):117-24. doi: 10.1097/NNR.0000000000000141. [PubMed: 26938360].
  • 5. Degenhardt L, Roxburgh A, Black E, Bruno R, Campbell G, Kinner S, et al. The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev. 2008;27(3):243-52. doi: 10.1080/09595230801950572. [PubMed: 18368605].
  • 6. McKetin R, Dunlop AJ, Holland RM, Sutherland RA, Baker AL, Salmon AM, et al. Treatment outcomes for methamphetamine users receiving outpatient counselling from the Stimulant Treatment Program in Australia. Drug Alcohol Rev. 2013;32(1):80-7. doi: 10.1111/j.1465-3362.2012.00471.x. [PubMed: 22642414].
  • 7. Wand H, Ward J, Bryant J, Delaney-Thiele D, Worth H, Pitts M, et al. Individual and population level impacts of illicit drug use, sexual risk behaviours on sexually transmitted infections among young Aboriginal and Torres Strait Islander people: Results from the GOANNA survey. BMC Public Health. 2016;16:600. doi: 10.1186/s12889-016-3195-6. [PubMed: 27435166]. [PubMed Central: PMC4950619].
  • 8. Massah O, Shishehgar S. Methamphetamine dependence, psychological well-being, criminality and high risk sexual behaviors in female-only methadone services in Tehran and Karaj, Iran. Iran J Psychiatry Behav Sci. 2018;12(2). e61859. doi: 10.5812/ijpbs.61859.
  • 9. Dana S, Effatpanah M, Mahjoub A. The new epidemic problem of psychoactive drugs at drug treatment centers of iran: Implications for education, prevention and treatment. Iran J Psychiatry Behav Sci. 2018;12(2). e63555. doi: 10.5812/ijpbs.63555.
  • 10. Noroozi A, Malekinejad M, Rahimi-Movaghar A. Factors influencing transition to shisheh (methamphetamine) among young people who use drugs in Tehran: A qualitative study. J Psychoactive Drugs. 2018;50(3):214-23. doi: 10.1080/02791072.2018.1425808. [PubMed: 29377788].
  • 11. Momtazi S, Noroozi A, Rawson RA. An overview of Iran drug treatment and harm reduction programs. In: el-Guebaly N, Carrà G, Galanter M, editors. Textbook of addiction treatment international perspectives. Verlag Italy: Springer; 2015. p. 543-54. doi: 10.1007/978-88-470-5322-9_25.
  • 12. DeMaria PA Jr, Sterling R, Weinstein SP. The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. Am J Addict. 2000;9(2):145-53. doi: 10.1080/10550490050173217. [PubMed: 10934576].
  • 13. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction. 2008;103(8):1242-57. doi: 10.1111/j.1360-0443.2008.02269.x. [PubMed: 18855813].
  • 14. De Letter EA, Piette MH, Lambert WE, Cordonnier JA. Amphetamines as potential inducers of fatalities: A review in the district of Ghent from 1976-2004. Med Sci Law. 2006;46(1):37-65. doi: 10.1258/rsmmsl.46.1.37. [PubMed: 16454462].
  • 15. Salimi S, Effatpanah M, Mahjoub A. Motivational interviewing can facilitate entry to matrix treatment for methamphetamine dependence. Iran J Psychiatry Behav Sci. 2018;12(2). e63560. doi: 10.5812/ijpbs.63560.
  • 16. Shakiba K, Effatpanah M, Moradi A. Cognitive-behavioral therapy for methamphetamine dependence among methadone-maintained patients. Iran J Psychiatry Behav Sci. 2018;12(2). e63615. doi: 10.5812/ijpbs.63615.
  • 17. Shadloo B, Amin-Esmaeili M, Haft-Baradaran M, Noroozi A, Ghorban-Jahromi R, Rahimi-Movaghar A. Use of amphetamine-type stimulants in the Islamic Republic of Iran, 2004-2015: A review. East Mediterr Health J. 2017;23(3):245-56. doi: 10.26719/2017.23.3.245. [PubMed: 28493273].
  • 18. Statistical Center of Iran (SCI). Selected findings of national population and housing census, 2016. Tehran: Vice Presidency for Strategic Planning and Supervision, Statistical Centre of Iran; 2016.
  • 19. Bureau of Planning and Information Technology. Year book of iran drug control headquarter, 2015. Presidency, Secretary of Drug Control Headquarter Publications; 2015.
  • 20. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, et al. Cohort profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010;39(1):52-9. doi: 10.1093/ije/dyp161. [PubMed: 19332502]. [PubMed Central: PMC3709199].
  • 21. Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Opium: An emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018. [PubMed: 23319416]. [PubMed Central: PMC3644384].
  • 22. Nalini M, Oranuba E, Poustchi H, Sepanlou SG, Pourshams A, Khoshnia M, et al. Causes of premature death and their associated risk factors in the Golestan Cohort Study, Iran. BMJ Open. 2018;8(7). e021479. doi: 10.1136/bmjopen-2018-021479. [PubMed: 30021753]. [PubMed Central: PMC6059279].
  • 23. Alam-mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian J Psychiatr. 2015;16:17-25. doi: 10.1016/j.ajp.2015.05.036. [PubMed: 26123235].
  • 24. Heikman P, Sundstrom M, Pelander A, Ojanpera I. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening. Hum Psychopharmacol. 2016;31(1):44-52. doi: 10.1002/hup.2512. [PubMed: 26763789].
  • 25. Peles E, Schreiber S, Linzy S, Domani Y, Adelson M. Differences in methylphenidate abuse rates among methadone maintenance treatment patients in two clinics. J Subst Abuse Treat. 2015;54:44-9. doi: 10.1016/j.jsat.2014.12.010. [PubMed: 25605438].
  • 26. De Boni RB, Shepherd BE, Grinsztejn B, Cesar C, Cortes C, Padgett D, et al. Substance use and adherence among people living with HIV/AIDS receiving cART in Latin America. AIDS Behav. 2016;20(11):2692-9. doi: 10.1007/s10461-016-1398-6. [PubMed: 27091028]. [PubMed Central: PMC5069110].
  • 27. Tran BX, Nguyen HLT, Le QNH, Mai HT, Ngo C, Hoang CD, et al. Alcohol and tobacco use among methadone maintenance patients in Vietnamese rural mountainside areas. Addict Behav Rep. 2018;7:19-25. doi: 10.1016/j.abrep.2017.11.005. [PubMed: 29450252]. [PubMed Central: PMC5805500].
  • 28. Nyamathi A, Hudson A, Greengold B, Leake B. Characteristics of homeless youth who use cocaine and methamphetamine. Am J Addict. 2012;21(3):243-9. doi: 10.1111/j.1521-0391.2012.00233.x. [PubMed: 22494226]. [PubMed Central: PMC3794708].
  • 29. Zule WA, Costenbader EC, Meyer WJ Jr, Wechsberg WM. Methamphetamine use and risky sexual behaviors during heterosexual encounters. Sex Transm Dis. 2007;34(9):689-94. doi: 10.1097/01.olq.0000260949.35304.22. [PubMed: 17471112].
  • 30. Semple SJ, Grant I, Patterson TL. Perceived behavior of others and AIDS risk behavior among heterosexually-identified methamphetamine users. J Psychoactive Drugs. 2006;Suppl 3:405-13. doi: 10.1080/02791072.2006.10400604. [PubMed: 17357532].
  • 31. Navadeh S, Mirzazadeh A, Gouya MM, Farnia M, Alasvand R, Haghdoost AA. HIV prevalence and related risk behaviours among prisoners in Iran: Results of the national biobehavioural survey, 2009. Sex Transm Infect. 2013;89 Suppl 3:iii33-6. doi: 10.1136/sextrans-2013-051295. [PubMed: 23986417]. [PubMed Central: PMC3841726].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments